The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new treatments, say Jirair Ratevosian and Jeffrey L Sturchio The arrival of ...

The once-daily oral GLP-1 RA orforglipron produces clinically and statistically significant weight loss and cardiometabolic ...

"Several preclinical and translational data studies suggest potential causative effects on bone health. One study with GLP-1 ...

Beyond GLP-1 RA prescriptions, chronic kidney disease (CKD) patients require comprehensive care from doctors, dietitians, & ...

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research Network, ...

Lung cancer patients who take medications called GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes ...

Li’s study employed the TriNetX U.S. Collaborative Research Network, which includes data from over 122 million patients. They queried for patients over the age of 18 years diagnosed with obesity, but ...

GLP-1 receptor agonists vs other second-line therapies were not associated with an increased thyroid cancer risk among patients with type 2 diabetes.

Use of SGLT2 inhibitors rather than GLP-1 receptor agonists is associated with lower risk of progression to kidney replacement therapy among patients with type 2 diabetes and CKD. The risk of ...

MONDAY, March 3, 2025 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an ...

Significantly lower risks seen for endometrial cancer, ovarian cancer, meningioma; nonsignificantly increased risk seen for kidney cancer.

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon-like ...